High Relaxivity MRI Contrast Agents based on a closo-borane platform
Shatadru Chakravarty 1,2 , Lixin Ma 1 , Lalit N. Goswami 1 , Satish S. Jalisatgi 1 , and M. Frederick Hawthorne 1
Radiology, International Institute of Nano
and Molecular Medicine-University of Missouri-Columbia,
Columbia, MO, United States,
Michigan State University, East Lansing, MI, United
The signal intensity and the overall detail and clarity
of an image obtained in an MRI exam is enhanced
spectacularly by the administration of chemical species
known as Contrast Agent (CAs). Despite several years of
research, the current batch of clinically approved CAs
are mostly small molecular weight species that suffer
from low relaxivity, poor tissue selectivity and
extremely short intravascular half-lives. We herein
report a novel class of CAs based on a closo-borane
framework with multifold improvements in relaxivity.
These multifunctional molecules are based on the novel
and unique twelve-fold functionalization of
closo-B12(OH)122- with a modified Gd- AAZTA chelate.
This abstract and the presentation materials are available to members only;
a login is required.